This week’s Medical Grand Rounds will be jointly presented by Dr. George Tsokos of @BIDMC_Rheum and Dr. Jon Arnason of @BIDMC_CancerCtr. Their talk is entitled, “The CAR-T Cell Journey, from Oncology to Rheumatology and Beyond.” Join us!
📅 February 27
🕖 8am
In this episode, we explore how polypharmacy, frailty, & multimorbidity shape care for older patients. We also dive into the 5Ms framework & the role of palliative care in #rheum. LISTEN NOW to learn more → https://t.co/sfnY8cTwXv @NamrataRheum
Why should rheumatologists care about aging?
As a herald to what was to come in Washington, the publication of the Lancet Rheumatology series on aging coming just days before #ACR24 set the stage for the “grey tsunami” of geriatric rheumatology that was to follow.
https://t.co/kfIPlR8afS
#Frailty
▶️Increasingly recognised in #rheumatic diseases
▶️Could be informative for risk assessment
▶️Potential modifiable target for treatment to improve quality of life & other adverse outcomes in rheumatic diseases
👉🏽https://t.co/7DXHKA4EZR
via @TheLancetRheum
#2606 @JihaRheum@BethIWallace @NamrataRheum
🔎 Focus: Late onset RA & GC use
Database: Medicare 2008-2017
💊 Exposure: DMARD use vs no use (within 12m)
#ACR24
🎤 Dr. Tsokos is currently presenting ‘Are We Putting the CAR-T Before the Horse?’ at #ACR24. Join us to explore the pioneering journey of cell therapies in rheumatic diseases. #BIDMCRheum#RheumTwitter#CART
RA patients affected by frailty at a younger age
in @VARA frailty associated with lower BMD
But frailty is modifiable!
#GeriRheum#ACR24@RheumNow ABST#2140
Older adults with late-onset RA (LORA) with more erosive changes, even with DMARD use
But is T2T met?
LORA with higher DAS on diagnosis and yet 10% on bDMARD vs 26% of young-onset RA
#ACR24@RheumNow ABST#2224
Presenting a rare case: metastatic arthropathy from hepatocellular carcinoma. Highlights the need for thorough diagnostics in atypical joint cases. #ACR24#BIDMCRheum